Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback